ArticleInternal and emergency medicine2026
Structured CEUS-based diagnostic pathway for newly detected splenic lesions: impact on diagnostic latency and advanced imaging use in a multicenter quality improvement study, with exploratory discrimination between hematologic and non-hematologic disease.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNewly detected splenic lesions represent a challenging diagnostic scenario in internal medicine, particularly when lymphoproliferative disease is suspected. Evidence on the role of contrast-enhanced ultrasound (CEUS) in this setting is limited, and its integration into structured clinical pathways has been poorly explored. This study evaluated the impact of a structured clinical-ultrasound diagnostic pathway incorporating CEUS on diagnostic latency and use of advanced imaging, as well as its exploratory ability to discriminate hematologic/lymphoproliferative from non-hematologic splenic lesions.
methodsWe conducted a multicenter, procedure-based quality Improvement study including 100 patients with newly detected splenic lesions. Fifty patients underwent a structured pathway based on an integrated clinical, laboratory, and ultrasound tool (intervention group), while 50 received standard management (control group). Primary outcomes were diagnostic latency and number of advanced imaging examinations (CT, MRI, PET). Secondary outcomes included the diagnostic performance of CEUS and of the integrated tool for discriminating hematologic/lymphoproliferative versus non-hematologic splenic lesions.
resultsMean diagnostic latency was significantly shorter in the intervention group (13.8 ± 21.2 vs 32.4 ± 35.7 days; p = 0.004). Median latency was 5 [IQR 3-14] versus 14 [IQR 3-30] days (p = 0.002). Early diagnoses (≤ 7 days) were more frequent in the intervention group (58% vs 22%), while delayed diagnoses (> 30 days) were more common in controls (38% vs 10%; p < 0.001). Use of advanced imaging was reduced in the intervention group (CT: 46% vs 100%, p < 0.001; PET: 4% vs 20%, p = 0.018). For the discrimination of hematologic/lymphoproliferative versus non-hematologic lesions, CEUS showed high sensitivity (90.9%) and good specificity (79.5%), whereas the integrated tool improved specificity (94.9%) while maintaining good sensitivity (81.8%).
conclusionsA structured CEUS-centered diagnostic pathway appears to shorten diagnostic latency and reduce advanced imaging use while maintaining adequate diagnostic accuracy. The diagnostic performance findings should be interpreted as exploratory and limited to binary stratification of hematologic/lymphoproliferative versus non-hematologic lesions, rather than lesion-specific diagnosis.
Indexed as
Identifiers
41945286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.